Research Monitoring
What changed
in the evidence.
Evidence is not static, and neither are our grades. This is the public log of what moved — new trials, regulatory actions, and every time we changed a compound's grade, with the source that prompted it.
Recent trial changes
Detected between ClinicalTrials.gov syncs · 2026-08-25Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults
Added to Synptide tracking
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Added to Synptide tracking
HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide
Added to Synptide tracking
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
Added to Synptide tracking
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
Added to Synptide tracking
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
Added to Synptide tracking
GLP-1s in Hip and Knee Arthroplasty
Added to Synptide tracking
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
Added to Synptide tracking
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
Added to Synptide tracking
Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics
Added to Synptide tracking
Tirzepatide for Treatment of CCCA
Added to Synptide tracking
Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes
Added to Synptide tracking
Recent trial activity
Auto-updated from ClinicalTrials.gov · synced 2026-08-25Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
A Retrospective Real-World Cohort Study
Incretin Therapies in Obesity-related HFpEF
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Semaglutide Therapy for Alcohol Reduction (STAR)
An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Evidence-grade change log
July 2026
Synptide launches the compound directory and evidence-grading system
We published canonical, outcome-graded profiles for the first 25 compounds, plus a public A–U evidence framework and this change log.
Semaglutide graded A for cardiovascular risk reduction on SELECT evidence
We set semaglutide's cardiovascular-outcome grade to A after the SELECT trial's 20% reduction in major cardiovascular events.